CD8A and neoplasm: Animal experiments showed that accumulation of SETDB1 mutations downregulates MHC-I-associated antigen presentation, thus preventing CD8+ T from correctly recognizing tumor cells and affecting sensitivity to PD-1/CTLA-4 treatment (38).